503 related articles for article (PubMed ID: 19838029)
1. [Assessment of chemotherapy-induced nausea and vomiting(CINV)using MASCC antiemesis tool].
Yamaguchi M; Ogawa T; Watanabe M; Anami S; Kamigaki S; Nishikawa N; Ono T; Furukawa H
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1691-6. PubMed ID: 19838029
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
Oshiro C; Kamigaki S; Nakamura Y; Arai T; Kanai Y; Fujino M; Fujii C; Hamaguchi Y; Iseki C; Hachino Y; Furukawa H
Gan To Kagaku Ryoho; 2012 Feb; 39(2):241-4. PubMed ID: 22333635
[TBL] [Abstract][Full Text] [Related]
3. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
6. [Comparative evaluation of 2 antiemesis tools for the prevention of chemotherapy-induced nausea and vomiting].
Murata H; Teramoto Y; Kawashita M; Oi M; Kitaguchi T; Sasahira E; Masuda A; Satake Y; Enomoto S; Komai C; Udo M; Komuta K; Yamamoto K
Gan To Kagaku Ryoho; 2014 Mar; 41(3):341-5. PubMed ID: 24743280
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
8. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
[TBL] [Abstract][Full Text] [Related]
10. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
Decker GM; DeMeyer ES; Kisko DL
J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
12. [An assessment tool for chemotherapy-induced nausea and vomiting and intervention outcomes].
Aimono Y; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2551-4. PubMed ID: 24335368
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
14. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
Wickham R
J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
[TBL] [Abstract][Full Text] [Related]
17. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
Tina Shih YC; Xu Y; Elting LS
Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
Grunberg SM
J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
[TBL] [Abstract][Full Text] [Related]
19. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.
Erazo Valle A; Wisniewski T; Figueroa Vadillo JI; Burke TA; Martinez Corona R
Curr Med Res Opin; 2006 Dec; 22(12):2403-10. PubMed ID: 17257454
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced nausea and vomiting.
Lohr L
Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
